# KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

> **NCT06411691** · PHASE1 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 54 (estimated)

## Conditions studied

- Colorectal Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** KRAS Vaccine with Poly-ICLC adjuvant
- **DRUG:** Balstilimab
- **DRUG:** Botensilimab

## Key facts

- **NCT ID:** NCT06411691
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-24
- **Primary completion:** 2028-03-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411691, "KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06411691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*